The FDA granted a new indication for avelumab (Bavencio, EMD Serono) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed on first-line platinum-containing chemotherapy.
For patients who do not progress on platinum-containing chemotherapy, avelumab is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.
The new indication is based on results from the phase 3 multicenter,